Patient description: A 65 yo male with no significant history of cardiovascular disease presents to the emergency room with acute onset of shortness of breath, tachypnea, and left-sided chest pain that worsens with inspiration. Of note, he underwent a right total hip replacement two weeks prior to presentation and was unable to begin physical therapy and rehabilitation for several days following the surgery due to poor pain management. Relevant physical exam findings include a respiratory rate of 35 and right calf pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ovarian Carcinoma Fallopian Tube Cancer Primary Peritoneal Cancer Subjects who have received at least one vaccine under protocol UPCC-19809 or UPCC-29810 ECOG performance status 0 or 1 Subject has sufficient vaccine (2 vaccine doses are sufficient) Must be at least 4 weeks post-operative Blood coagulation parameters: PT such that international normalized ratio (INR) is less than1.5 (or an in-range INR, usually between 2 and 3, if a subject is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolus) and a PTT less than1.2 times the upper limit of normal Subject must be 18 years of age or older Life expectancy of greater than 4 months Normal organ and bone marrow function as defined by: Absolute neutrophil count greater than 1,000/microliter, Platelets greater than 100,000/microliter, Hematocrit greater than 30%, AST (SGOT)/ALT(SGPT) less than 2.5 X institutional upper limit of normal, Bilirubin less than 2.0 mg/dL unless secondary to bile duct blockage by tumor, and Creatinine less than 1.8 mg/dL  Subjects who require or are likely to require more than a two-week course of corticosteroids for intercurrent illness. Subjects must complete therapy prior to enrollment. Topical corticosteroids should be stopped at least 2 weeks prior to enrollment and systemic corticosteroids should be stopped at least 4 weeks prior to enrollment Subjects with any acute infection that requires specific therapy. Acute therapy must have been completed at least seven days prior to study enrollment Subjects with any underlying conditions, which would contraindicate therapy with, study treatment (or allergies to reagents used in this study) Subjects with prior history or symptoms suggestive of partial or complete bowel obstruction Subjects receiving class III antiarrythmic medications Subjects receiving medications that might affect immune function. Additionally, H2 blockers are excluded, as are all antihistamines five days before and five days after each injection of study drug. NOTE: The following are exceptions: Proton pump Inhibitors (PPIs), including COX-2 inhibitors, acetaminophen Subjects who are allergic to Aspirin are excluded Development of clinically significant co morbid disease that would contraindicate study therapy or confuse interpretation of study results Subjects with a History of bowel obstruction, including sub-occlusive disease, related to the underlying disease and history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess Subjects with evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction